A post hoc analysis of the GATHER1 clinical trial on Zimura, an investigational new therapy for geographic atrophy, showed the potential to rely on OCT to measure the effect of the treatment on disease progression.
According to a press release from Iveric Bio, manufacturer of Zimura (avacincaptad pegol), “the results of the post hoc analysis showed that OCT-measured GA area strongly correlated with FAF-measured GA area, with minimal average differences in GA area between modalities.”
Fundus autofluorescence (FAF), an imaging modality typically used in geographic atrophy (GA)